Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	123385
DOI	10.4251/wjgo.123385
Country	China

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Fei Ma, Li-Yun Zheng, Dan-Jun Song, Zhong-Wei Zhao, Fei Cao, Wei-Yuan Hao, Jun-Qi Qiu, Dong Lu and Jia-Ping Zheng
Funding Agency and Grant Number
Corresponding Author	Jia-Ping Zheng, MD, PhD, Professor, Department of Interventional Therapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Banshan East Road, Hangzhou 310022, Zhejiang Province, China. zhengjp@zjcc.org.cn
Key Words	Unresectable hepatocellular carcinoma; Regorafenib; Programmed cell death-1 inhibitor; Second-line treatment; Prognostic factors
Core Tip	This multicenter retrospective study provides real-world evidence supporting regorafenib plus programmed cell death-1 (PD-1) inhibitors as second-line therapy for unresectable hepatocellular carcinoma after first-line treatment failure. Combination therapy improved disease control and prolonged progression-free and overall survival. Notably, survival benefit was mainly observed in patients with prior immune checkpoint inhibitor exposure, whereas first-line targeted therapy (lenvatinib or sorafenib) did not influence second-line outcomes. Second-line PD-1 inhibitor therapy independently predicted progression-free survival.
Citation	Ma F, Zheng LY, Song DJ, Zhao ZW, Cao F, Hao WY, Qiu JQ, Lu D, Zheng JP. Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; In press DOI: https://doi.org/10.4251/wjgo.123385
PDF	123385-in-press.pdf

Received	2026-05-18 08:27
Peer-Review Started	2026-05-18 08:27
First Decision by Editorial Office Director
Return for Revision	2026-06-16 07:35
Revised	2026-06-29 16:55
Publication Fee Transferred	2026-07-07 02:52
Second Decision by Editor	2026-07-16 02:41
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-07-16 06:20
Articles in Press	2026-07-16 06:20
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com